A Survey of Lanadelumab in Participants with Hereditary Angioedema

Launched by TAKEDA · May 26, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at the use of a medication called Lanadelumab to treat people with hereditary angioedema (HAE), a condition that causes sudden swelling in various parts of the body. The study is being conducted in Japan and will focus on understanding how well Lanadelumab works and if it causes any side effects. Participants who are diagnosed with HAE and are starting treatment with Lanadelumab for the first time are eligible to join the study.

During the trial, participants will receive Lanadelumab through an injection under the skin, following the usual treatment practices of their clinic. Over the course of 12 months, doctors will monitor participants for any side effects and assess how their symptoms improve. This study is open to all genders, and there are no specific age limits mentioned. It aims to gather important information that could help better manage HAE in the future.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria - Participants diagnosed with hereditary angioedema (HAE) and treated with Lanadelumab for the first time.
• • Exclusion Criteria
• • - None